Disc Medicine, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$50,334	$24,685	$124,416	$71,874
Selling, general and administrative	17,362	8,171	44,636	23,296
Total operating expenses	67,696	32,856	169,052	95,170
Loss from operations	(67,696)	(32,856)	(169,052)	(95,170)
Other income (expense), net:
Interest income	6,412	6,362	20,349	15,454
Interest expense	(917)	—	(2,724)	—
Other income (expense)	(18)	9	47	(5)
Total other income (expense), net	5,477	6,371	17,672	15,449
Loss before income taxes	(62,219)	(26,485)	(151,380)	(79,721)
Income tax expense	(102)	(114)	(273)	(179)
Net loss	$(62,321)	$(26,599)	$(151,653)	$(79,900)
Net loss per share, basic and diluted	$(1.77)	$(0.89)	$(4.39)	$(2.98)
Weighted-average common shares outstanding, basic and diluted	35,178,691	29,935,551	34,516,134	26,809,605
Comprehensive loss:
Net loss	$(62,321)	$(26,599)	$(151,653)	$(79,900)
Other comprehensive income:
Foreign currency translation adjustments	—	(48)	(1)	(42)
Unrealized gain on marketable securities	445	849	430	783
Total other comprehensive income	445	801	429	741
Comprehensive loss	$(61,876)	$(25,798)	$(151,224)	$(79,159)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.